Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Glaxo Wellcome |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002200 |
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
Condition | Intervention |
---|---|
HIV Infections |
Drug: Abacavir sulfate |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | A 1592U89 Open-Label Protocol for Adult Patients With HIV-1 Infection. |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Erythropoietin, G-CSF and GM-CSF.
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Required:
At least 2 nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (or intolerance to one protease inhibitor and one NRTI due to trying at least 2 different regimens with at least one protease inhibitor).
Alcohol or illicit drug use that may interfere with the patient's compliance.
Study ID Numbers: | 238M, CNAA3008 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002200 |
Health Authority: | United States: Food and Drug Administration |
HIV-1 Administration, Oral CD4 Lymphocyte Count RNA, Viral |
Reverse Transcriptase Inhibitors Anti-HIV Agents Viral Load abacavir |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Abacavir Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents Communicable Diseases RNA Virus Infections Anti-HIV Agents Slow Virus Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Reverse Transcriptase Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections Nucleic Acid Synthesis Inhibitors |